Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy

BACKGROUND: The optimal timing to initiate bevacizumab (BV) therapy for recurrent glioblastoma (GBM) is currently unclear. To address this issue, we examined progression-free survival (PFS) and survival time (ST) in a large retrospective cohort of GBM patients treated with BV at different recurrence...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Main Authors: Piccioni, David E., Selfridge, Julia, Mody, Reema R., Chowdhury, Reshmi, Li, Sichen, Lalezari, Shadi, Wawrzynski, James, Quan, Jennifer, Zurayk, Mira, Chou, Arthur P., Sanchez, Desiree E., Liau, Linda M., Ellingson, Benjamin M., Pope, Whitney B., Nghiemphu, Phioanh L., Green, Richard M., Wang, He-jing, Yong, William H., Elashoff, Robert, Cloughesy, Timothy F., Lai, Albert
Formáid: Artigo
Teanga:Inglês
Foilsithe: Oxford University Press 2014
Ábhair:
Clinical Investigations
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4022228/
https://ncbi.nlm.nih.gov/pubmed/24627236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou028
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla